Nuvectis Posts Q2 Loss, But $115M Raise and Ciprocopan Approval in China Fuel Pipeline Push
NVCT has more than doubled off its 52-week low of $5.55.
Summary
Nuvectis reported a Q2 net loss of $7.0M, slightly wider than the $6.3M loss a year ago, with cash at $22.2M as of June 30. The real story is the $115M follow-on offering completed in July, which extends the cash runway into the first half of 2029 and funds the push toward U.S. regulatory filings for lead asset ciprocopan. Ciprocopan just won its first marketing approval in China for treatment-naive PNH, validating the oral Factor B inhibitor approach. The company now plans a pre-IND meeting with the FDA and IND submission in Q4 2026, aiming to replicate that success in the U.S. and other territories. Meanwhile, the oncology pipeline is advancing: NXP200 Phase 1b data will be presented at ESMO in October, with a U.S. IND also expected in Q4, and NXP900 combination trials in NSCLC and pancreatic cancer are moving forward. The offering was anchored by leading healthcare investors, signaling institutional confidence despite the dilutive impact. With a clear regulatory path and funded operations, the focus shifts to execution on the ciprocopan U.S. filing.
At the time of this announcement, NVCT was trading at $21.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $681M. The 52-week trading range was $5.55 to $29.28. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.